Pharmacoanalytic Core Laboratory

药物分析实验室（PAL）的使命是提供智力和分析支持 基础、转化和临床科学家。对于基础科学研究人员，PAL有助于 从“试管”到潜在的临床模式。潜在抗癌或 使用体外和体内模型进一步开发了源自实验室概念的诊断剂 在PAL的智力支持下开发。对于临床医生，PAL提供分析和 药代动力学/药效学支持，以进一步了解可能 影响临床结果。 为了满足这些需求，PAL已经获得了开发特定分析工具的能力。 和基于生物学的技术，以支持基础，转化和临床为基础的努力。这包括 通过使用ELISA和液相色谱开发高灵敏度的定量方法 串联质谱（LC-MS/MS）技术。基于LC-MS/MS的技术可以最大限度地减少 所需的样品体积，从而允许在儿科人群中进行系列药物分析， 小动物。此外，PAL还开发了使用LC-MS/MS测定细胞内 浓度的核苷和它们的拮抗剂，包括活化的组分，三磷酸 个核苷酸这些技术也可用于分析细胞内核苷酸库，以研究细胞内的 导致核苷耐药的机制。此外，PAL还在临床设计方面进行合作 具有药代动力学成分的方案，并评估人体药代动力学结果 问题研究 尽管有这些发展，巴援委仍保持并加强了其核心分析能力， 使用基于HPLC的分析，利用UV和荧光检测。这些测定是可靠的分析 能够支持要求药物水平测定的临床方案的能力。PAL培养了一个 环境，以加强基础，转化和临床科学家之间的合作。

The mission of Pharmacoanalytical Laboratory (PAL) is to provide intellectual and analytical support to basic, translational and clinical scientists. For basic science investigators, the PAL assists in the development of discoveries from the "test tube" to potential clinical modalities. Potential anticancer or diagnostic agents derived from laboratory concepts are further developed using in vitro and in vivo models developed with intellectual support from the PAL. For clinicians, the PAL provides analytical and pharmacokinetic/pharmacodynamics support to further understand the underlying mechanisms that may influence clinical outcome. In an effort to meet these needs, the PAL has acquired the capacity to develop specific analytical and biologically-based techniques to support basic, translational and clinically-based efforts. This includes the development of highly sensitive quantification methods by using ELISA- and liquid chromatography tandem mass spectrometry (LC-MS/MS)-based technology. LC-MS/MS-based technology can minimize the amount of sample volume required, thus allowing serial drug analysis in pediatric populations and even in small animals. In addition, the PAL has developed methods using LC-MS/MS to determine intracellular concentration nucleosides and their anabolites that include the activated component, the triphosphate nucleotides. These techniques can also be used to analyze intracellular nucleotide pools to study cellular mechanisms that lead to nucleoside resistance. In addition, the PAL collaborates in the design of clinical protocols having a pharmacokinetic component and evaluates the results of human pharmacokinetic studies. Despite these developments, the PAL has maintained and enhanced its core analytical capacity using HPLC-based assays utilizing UV and fluorescence detection. These assays are reliable analytical capabilities that can support clinical protocols that mandate drug level determinations. The PAL fosters an environment to enhance collaboration between basic, translational and clinical scientists.